RXST: financial statements from SEC — TradeAlmanac

RXST

RxSight, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	31m	30m	34m	38m	35m	35m
Cost of revenue	7m	6m	8m	10m	10m	11m
Gross profit	23m	24m	25m	28m	25m	24m
Research and development	9m	9m	10m	10m	9m	8m
Selling, general and administrative	32m	27m	29m	29m	26m	24m
Operating expenses	41m	36m	39m	39m	34m	33m
Operating income	−18m	−12m	−14m	−11m	−9m	−8m
Interest expense	3,000	4,000	5,000	6,000	5,000	6,000
Pre-tax income	−16m	−10m	−12m	−8m	−6m	−6m
Income tax	6,000	10,000	32,000	18,000	13,000	16,000
Net income	−16m	−10m	−12m	−8m	−6m	−6m
Earnings per share	−0.38	−0.24	−0.29	−0.20	−0.16	−0.16
Earnings per share, diluted	−0.38	−0.24	−0.29	−0.20	−0.16	−0.16
Weighted average shares	41m	41m	41m	41m	40m	38m
Weighted average shares, diluted	41m	41m	41m	41m	40m	38m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	18m	20m	30m	40m	28m	17m	17m	25m
Short-term investments	200m	208m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−11m	−9m
Depreciation and amortisation	834,000	776,000
Share-based compensation	8m	7m
Capital expenditure	759,000	575,000
Investing cash flow	9m	21m
Financing cash flow	−336,000

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)